ANTABIO
Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. It develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. The company's novel inhibitor of bacterial Metallo ß-lactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the tr... eatment of drug-resistant infections. They develop a novel, safe and efficacious inhibitor of bacterial Metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections. Antabio received a Wellcome Trust Seeding Drug Discovery Award. The company was founded in 2009 and is headquartered in Labege, France.
ANTABIO
Industry:
Biotechnology Life Science Medical Device
Founded:
2009-01-01
Address:
Labège, Midi-Pyrenees, France
Country:
France
Website Url:
http://www.antabio.com
Total Employee:
11+
Status:
Active
Contact:
+33 5 61 53 88 43
Email Addresses:
[email protected]
Total Funding:
73.09 M USD
Technology used in webpage:
Google Maps HSTS Common Name Invalid LiteSpeed Oracle Cloud French Server Location
Similar Organizations
BAROnova
BAROnova is a clinical-stage medical-device company focused on developing non-surgical non-pharmacologic devices to induce weight loss.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
CStone Pharmaceuticals
CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Instadiagnostics
Instadiagnostics Inc., is developing a rapid, quantitative, point-of-care (POC) diagnostic platform.
Iroko Pharmaceuticals
Iroko Pharmaceuticals is a global specialty pharmaceutical company dedicated to advancing the science of analgesia.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
IRDI SORIDEC Gestion
IRDI SORIDEC Gestion investment in Series B - Antabio
BNP Paribas Développement
BNP Paribas Développement investment in Series B - Antabio
European Innovation Council
European Innovation Council investment in Series B - Antabio
Christophe Ricard
Christophe Ricard investment in Series B - Antabio
AMR Action Fund
AMR Action Fund investment in Series B - Antabio
Turenne Capital
Turenne Capital investment in Series B - Antabio
European Innovation Council
European Innovation Council investment in Grant - Antabio
European Innovation Council
European Innovation Council investment in Venture Round - Antabio
CARB-X
CARB-X investment in Grant - Antabio
BNP Paribas Développement
BNP Paribas Développement investment in Series A - Antabio
Official Site Inspections
http://www.antabio.com
- Host name: cluster010.hosting.ovh.net
- IP address: 213.186.33.19
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Antabio"
Antabio - Crunchbase Company Profile & Funding
Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet …See details»
Team and Advisors - antabio.com
Antabio develops stand-alone inhibitors of bacterial metalloenzymes. Combined with …See details»
About Antabio
Antabio is a privately-held clinical-stage biopharmaceutical company developing novel and …See details»
Antabio Company Profile: Overview and Full News Analysis
Antabio is a clinical-stage biopharmaceutical company located in Midi-Pyrenees, focused on …See details»
Antabio Company Profile 2024: Valuation, Funding & Investors
When was Antabio founded? Antabio was founded in 2009. Where is Antabio headquartered? …See details»
Antabio - Funding, Financials, Valuation & Investors - Crunchbase
Antabio is a private biopharmaceutical company developing antibacterial resistance-breakers in …See details»
Antabio - VentureRadar
Acurx Pharmaceuticals, LLC USA n/a Acurx Pharmaceuticals, Inc. is a publicly held, clinical …See details»
Antabio Company Profile - Office Locations, Competitors ... - Craft
Antabio has 5 employees at their 1 location and $41.11 m in total funding,. See insights on …See details»
Antabio - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Antabio . Connect to CRM . Save . Summary. Financials. People. Technology. …See details»
History and keyfacts - Antabio
ANTABIO Raises €25 million in Series B Financing. Led by the AMR Action Fund, with subscriptions from the EIC Fund and from Antabio’s historical investors, the financing will be used to support the clinical development of MEM-ANT3310 …See details»
Antabio SAS - BIO CEO & Investor Conference | BIO
Feb 6, 2023 Antabio's team includes former management and executives from Novexel, GSK, …See details»
Antabio Announces First Subjects Dosed in Phase 1 Clinical
May 25, 2023 Antabio’s portfolio includes two further programs: 1) ANT3273, a …See details»
Antabio Awarded $4.4 Million From CARB-X for the Further …
TOULOUSE, France, Jan. 2, 2020 /PRNewswire/ -- Antabio SAS, the biopharmaceutical …See details»
Antabio Receives QIDP Designation From the U.S. FDA for the …
LABÈGE, France, May 6, 2020 /PRNewswire/ -- Antabio SAS, the biopharmaceutical company …See details»
Antabio Management
Antabio develops stand-alone inhibitors of bacterial metalloenzymes. Combined with …See details»
Antabio on quest to tackle antibiotic resistance
May 26, 2023 The World Health Organization considers antibiotic resistance to be one of the …See details»
News - Antabio
Antabio SAS is pleased to announce the appointment of Dr. Erick Lelouche as Chairman of the …See details»
Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of …
May 25, 2023 MEM-ANT3310 has the potential to become the next standard of care for life …See details»
About AMR - Antabio
Antimicrobial resistance is a growing global health problem recognized as n°1 priority by the …See details»